Gestational trophoblastic disease / neoplasia: options by country
Treatment options for Gestational trophoblastic disease / neoplasia mapped across 6 countries — covering chemotherapy, clinical trials, immunotherapy and radiation — each linking to its regulator, HTA, or guideline source, with questions to bring to your care team. Options, not recommendations.
Options mappedRare diseaseLast checked June 2026
Options by country
Treatments by country
Regulatory and access status by country, from official sources. It shows what exists and where — not a recommendation.
Monitoring/advisory follow-up, chemotherapy, surgery in selected cases, specialist GTD clinic assessment[3]Standard option (per Imperial College Healthcare NHS Trust)hCG monitoring implied by GTD service follow-up; no molecular biomarker specified in the fetched Imperial page; GTD follow-up/monitoring; cases needing additional treatment; specialist clinic assessment. · This source documents a specialist-service pathway and broad treatment categories, not specific chemotherapy regimens, eligibility, or national commissioning rules. Confidence/conflicts: High for the Charing Cross specialist-service and broad treatment pathway; regimen-level detail should use dedicated treatment sources.
This is official regulatory and access status only — not medical advice, not a recommendation, and not a statement about eligibility. Whether any option fits depends on your situation and your oncology team. Status changes over time; confirm the current position with the linked source. Last checked June 2026.
Beyond approved care
In clinical trials & emerging options
Options that are not — or not yet — an approved standard where you live: studies, clinical trials, off-label use, and early evidence that your own oncologist may not raise. Each is labeled by how strong the evidence is. A listing here is information to research and discuss with your team; it does not mean a treatment is proven, safe for you, or available today.
In clinical trials
Avelumab plus methotrexate; avelumab; domvanalimab plus zimberelimab with or without FOLFOX-4; French National Reference Centre registry/observational pathwayClinical trial · NCT04396223Clinical trialTrial only (registry)European Union · Low-risk GTN first-line; chemo-resistant GTN; advanced rare-cancer platform including gestational trophoblastic tumor; national reference-centre GTD registry context. · Some records are interventional treatment studies; the French National Reference Centre record is registry/reference-centre context without an intervention listed. Trial participation and reference-centre registry inclusion should not be represented as approved access. Confidence/conflicts: High for France-site registry support; no EMA/ANSM/HAS access claim is made. ClinicalTrials.gov — clinical-trial registry
Dactinomycin; methotrexate; leucovorin calcium; quality-of-life assessmentClinical trial · NCT01535053Clinical trialTrial only (registry)Japan · Low-risk gestational trophoblastic neoplasia, including choriocarcinoma and FIGO stage I-III gestational trophoblastic tumor/hydatidiform mole contexts in the registry conditions. · The study is completed. Registry location text supports trial participation history in these countries, not current enrollment or local standard-of-care access. Confidence/conflicts: High for country-site and trial-context support; no regulator approval claim is made. reimbursement not established in this jurisdiction trial-registry listing only — does not establish approval, reimbursement, or eligibility ClinicalTrials.gov — clinical-trial registry
Pembrolizumab (Keytruda); pembrolizumab before second evacuation for post-molar GTNClinical trial · NCT04303884Clinical trialTrial only (registry)Korea · Chemo-resistant GTN for the South Korea record; post-molar GTN before second evacuation for the UK record. · Study statuses differ: unknown for the South Korea trial and recruiting for the UK trial. Immunotherapy should not be generalized to all GTN settings from these registry records. Confidence/conflicts: High for registry support; medium for current availability because one study status is unknown and neither source is a regulator/HTA document. ClinicalTrials.gov — clinical-trial registry
A clinical-trial listing or early report shows an option is being studied — not that it works, that it is safe for any one person, or that a site is enrolling today. Whether any of these fits is a conversation for your oncology team and the trial team. Last checked June 2026.
What this page does
Maps options by country
It maps sourced options by country alongside diagnosis wording, stage, test results, specialists, and trial-search terms.
What it does not do
Does not choose treatment
It does not rank treatments, recommend a choice, or decide clinical fit.
Where it comes from
Built on trusted sources
Every option links to a trusted regulator, HTA, or guideline source, and the list grows as new sources pass verification.
Information to gather before the next visit
What is the exact diagnosis and risk category: low-risk GTN, high-risk metastatic GTN, PSTT, ETT, recurrent, or chemoresistant disease?
Is beta-hCG monitoring showing response, resistance, or recurrence?
Is the treatment question single-agent chemotherapy, combination chemotherapy, surgery, brain-directed therapy, or a clinical trial?
Which UK specialist GTD centre is coordinating care?